Key facts
- It has raised $17.3M.
- Notable investors include Plug and Play Tech Center, Creative Destruction Lab, University of Toronto, University of Toronto Entrepreneurship, LifeArc — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Oxford Cancer Analytics
- ·The full record, as it builds
Funding rounds
No funding rounds for Oxford Cancer Analytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oxford Cancer Analytics
Developer of an artificial intelligence-based healthcare platform designed to identify cancers through targeted blood testing. The company's platform cost-effectively and routinely detects cancer materials shed into the blood, analyzing multidimensional liquid biopsy results that include DNA, proteins, epigenetics, epidemiology, and patient medical history, enabling healthcare providers to achieve early cancer detection and curative treatment.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2018
- Employees
- 25
- Website
- oxcan.org/
- Ownership
- Privately Held (backing)
Oxford Cancer Analytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oxford Cancer Analytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oxford Cancer Analytics in its N-PORT filings yet. We sweep new filings monthly.